uFraction8 Limited has successfully secured a £3.4m funding round led by Foresight Group to advance its pioneering microfluidics-based bioprocessing technologies.

Target Company Overview

uFraction8 Limited, established in 2017, is a prominent provider of microfluidics-based bio-separation technology, operating across Scotland and Poland. The company, founded by Dr. Monika Tomecka (CEO) and Dr. Brian Miller (CTO), is renowned for its breakthrough research which was published in the prestigious Nature journal. uFraction8 is dedicated to commercializing an innovative technology that facilitates continuous bioprocessing of mammalian cell lines, stem cells, and microalgae at scale, addressing critical issues within the industry.

The proprietary technology offered by uFraction8 optimizes production by significantly increasing yield, offering reusability, and reducing downtime compared to traditional methods. This reusable, patent-protected system can scale production volumes by as much as 20 times to reach 20,000 liters, while achieving over 99% yield. The company's approach presents a sustainable and energy-efficient alternative for the bioprocessing landscape, supported by applications in key markets including microalgae, biopharmaceuticals, and alternative proteins.

Industry Overview

The bioprocessing industry, particularly in the UK, is witnessing rapid growth driven by advancements in technology and rising demand for biopharmaceutical products. The market is expected to expand due to the burgeoning interest in biologics, whi